Atom’s core assets are novel orally administered drugs in late stage clinical development to address the escalating global crisis of chronic and acute gout associated with hyperuricemia.
Lingdolinurad (ABP-671) is a new generation of URAT1 inhibitors in global Phase 3 trials for chronic, refractory and tophaceous gout. This URAT1 inhibitor has demonstrated higher potency and good safety and tolerability compared to existing urate-lowering therapies.
ABP-745 is a novel anit-inflammarotry drug with similar mechanism of action to colchicine and has demonstrated a favorable safety and efficacy profile compared to colchicine. ABP-745 is in Phase 2 trials for acute gout flares. Additional Phase 2 trials are ongoing for atherosclerotic cardiovascular disease and IND submissions for heart failure with preserved ejection fraction and pericarditis are planned in Q4 2026.